Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378995 (Preparation of {3-[({2-[1-(4-ethoxy-2,6-difluorobe...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM415317 (Preparation of 3-{[2-(hydroxymethyl)phenyl]amino}-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.58 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ... | US Patent US10428044 (2019) BindingDB Entry DOI: 10.7270/Q2QF8W7J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378915 (2-[1-(6-chloro-2-fluoro-3-methylbenzyl)-1H-indazol...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378932 (2-[1-(6-chloro-2- fluoro-3- methoxybenzyl)- 1H-ind...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367598 (US10227299, Example 288) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367317 (Methyl (6RS)-4-oxo-3-(phenylamino)-2-(pyridin-4-yl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379026 (Preparation of 1-[3,5-difluoro-4-({3-[5-methoxy-4-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379042 (Preparation of 2-({2-[1-(4-ethoxy-2,6-difluorobenz...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379006 (US10266548, Example 4-2-1 | {3[({2-[1-(2- fluorobe...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM415374 (Preparation of 3-{[5-fluoro-2-(hydroxymethyl)pheny...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.35 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ... | US Patent US10428044 (2019) BindingDB Entry DOI: 10.7270/Q2QF8W7J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379107 (Preparation of 5-(2-aminoethoxy)-2-[1-(4-ethoxy-2,...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379108 (2-[1-(4-ethoxy-2,6- difluorobenzyl)-1H- indazol-3-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM415373 (Preparation of 3-{[3-fluoro-2-(hydroxymethyl)pheny...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.45 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ... | US Patent US10428044 (2019) BindingDB Entry DOI: 10.7270/Q2QF8W7J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM415303 (Intermediate 1-2-69 | US10428044, Example 410) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.55 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ... | US Patent US10428044 (2019) BindingDB Entry DOI: 10.7270/Q2QF8W7J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379024 (Preparation of 2-[1-(4-cyclopropyl-2,6-difluoroben...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.90 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM415283 (Preparation of 1-(1-methyl-1H-pyrazol-4-yl)-3-{4-[...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.96 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ... | US Patent US10428044 (2019) BindingDB Entry DOI: 10.7270/Q2QF8W7J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM395282 (N-{4-[[(4aR,5aR) or (4aS,5aS)]-3-Anilino-5a-methyl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4 | n/a | n/a | n/a | n/a | n/a | n/a |
GSK | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | Bioorg Med Chem Lett 19: 3674-8 (2009) BindingDB Entry DOI: 10.7270/Q2NZ89ZG | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367367 (N-Methyl-4-oxo-3-(phenylamino)-N-propyl-2-(pyridin...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367368 (N,N-Dimethyl-4-oxo-3-(phenylamino)-2-(pyridin-4-yl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367372 ((6RS)-6-[(Ethylsulfanyl)methyl]-3-(phenylamino)-2-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367593 (US10227299, Example 283) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM395252 ((4aS,5aS or 4aR,5aR)-3-(Phenylamino)-2-(pyridin-4-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4 | n/a | n/a | n/a | n/a | n/a | n/a |
GSK | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | Bioorg Med Chem Lett 19: 3674-8 (2009) BindingDB Entry DOI: 10.7270/Q2NZ89ZG | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM414909 (Preparation of 3-(phenylamino)-6-(propan-2-yl)-2-(...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.04 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ... | US Patent US10428044 (2019) BindingDB Entry DOI: 10.7270/Q2QF8W7J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM415365 (Preparation of 1-benzyl-N-{4-[6,6-dimethyl-4-oxo-3...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.23 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ... | US Patent US10428044 (2019) BindingDB Entry DOI: 10.7270/Q2QF8W7J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM415336 (Preparation of 1-benzyl-N-{4-[4-oxo-3-(phenylamino...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.38 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ... | US Patent US10428044 (2019) BindingDB Entry DOI: 10.7270/Q2QF8W7J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378946 (2-[1-(2-chloro- 4,5- dimethylbenzyl)- 1H-indazol-3...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM415357 (Preparation of N-{4-[4′-oxo-3′-(phenyl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.49 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ... | US Patent US10428044 (2019) BindingDB Entry DOI: 10.7270/Q2QF8W7J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378960 (2-[1-(2,6- difluoro-3- methoxybenzyl)- 1H-indazol-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM415284 (Preparation of 1-{4-[6,6-dimethyl-4-oxo-3-(phenyla...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.52 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ... | US Patent US10428044 (2019) BindingDB Entry DOI: 10.7270/Q2QF8W7J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378973 (2-[1-(4-ethoxy- 2,6- difluorobenzyl)- 1H-indazol-3...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379040 (Preparation of (2R)-3-({2-[1-(2-fluorobenzyl)-1H-i...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379040 (Preparation of (2R)-3-({2-[1-(2-fluorobenzyl)-1H-i...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM415331 (2-{[(2-aminopyridin-4-yl)methyl]amino}-4-({[tert-b...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.61 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ... | US Patent US10428044 (2019) BindingDB Entry DOI: 10.7270/Q2QF8W7J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378991 (Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379045 (4-({2-[1-(2- fluorobenzyl)- 1H-indazol-3-yl]- 5-(2...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378980 (2-[1-(2-chloro-4- methoxybenzyl)- 1H-indazol-3-yl]...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM341151 (4-({2-[4-chloro-5-cyclopropyl-1-(4-ethoxy-2,6-difl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Bayer Pharma Aktiengesellschaft US Patent | Assay Description In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ... | US Patent US9765058 (2017) BindingDB Entry DOI: 10.7270/Q2JQ1347 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379041 ((2S)-3-({2-[1-(2- fluorobenzyl)- 1H-indazol-3-yl]-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | KEGG PC cid PC sid UniChem | US Patent | n/a | n/a | 4.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378982 (2-[1-(2,6- difluorobenzyl)- 1H-indazol-3-yl]- 5-me...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379103 (Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.91 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM395280 (N-4-[[(4aS,5aS) or (4aR,5aR)]-5a-Methyl-4-oxo-3-(p...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
GSK | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | Bioorg Med Chem Lett 19: 3674-8 (2009) BindingDB Entry DOI: 10.7270/Q2NZ89ZG | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367507 ((6RS)-2-2-[(4-Fluorobenzoyl)amino]pyridin-4-yl-N,N...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367371 ((6RS)-3-(Phenylamino)-6-[(propan-2-ylsulfanyl)meth...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367349 ((6RS)-6-Ethenyl-3-(phenylamino)-2-(pyridin-4-yl)-1...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367592 (US10227299, Example 282) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367590 (US10227299, Example 280) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367472 (Methyl (6RS)-2-[3-(2-methoxyethoxy)pyridin-4-yl]-4...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM367412 ((6RS)N-Methyl-N-(2-methylpropyl)-4-oxo-3-(ph...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 1377-84 (2008) BindingDB Entry DOI: 10.7270/Q2QN6931 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM395255 ((4aR,5aR or 4aS,5aS)-5a-Methyl-3-(phenylamino)-2-(...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
GSK | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | Bioorg Med Chem Lett 19: 3674-8 (2009) BindingDB Entry DOI: 10.7270/Q2NZ89ZG | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM50011209 (CHEMBL3260324) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | CHEMBL PC cid PC sid UniChem Patents Similars | Article PubMed | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Dart Neuroscience LLC Curated by ChEMBL | Assay Description Inhibition of Bub1 kinase (unknown origin) by TR-FRET kinase assay | ACS Med Chem Lett 5: 280-1 (2014) Article DOI: 10.1021/ml5000492 BindingDB Entry DOI: 10.7270/Q2XG9SN8 | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 1082 total ) | Next | Last >> |